Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 6/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1277281 | 0.90 | APP (0.43) | F10PRSS1APP | |
| SCHEMBL1277175 | 0.89 | F10 (0.34) | F10 | |
| SCHEMBL1277133 | 0.89 | F10 (0.37) | F10PRSS1 | |
| SCHEMBL1277373 | 0.86 | F10 (0.39) | F10PRSS1APPLMNA | |
| SCHEMBL1277277 | 0.85 | BACE1 (0.40) | F10PRSS1 | |
| SCHEMBL1277774 | 0.85 | F10 (0.37) | F10PRSS1APP | |
| SCHEMBL1708746 | 0.85 | F10 (0.33) | F10PRSS1 | |
| SCHEMBL1277698 | 0.85 | MAPT (0.36) | F10LMNAMAPT | |
| SCHEMBL1277389 | 0.84 | BAZ2B (0.38) | F10 | |
| SCHEMBL1708745 | 0.83 | F10 (0.35) | F10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088737-A2 | NOVEL ACYL GUANIDINE DERIVATIVES | AJINOMOTO CO., INC (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20120088737-A2 | NOVEL ACYL GUANIDINE DERIVATIVES | AJINOMOTO CO., INC (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20120088737-A2 | NOVEL ACYL GUANIDINE DERIVATIVES | AJINOMOTO CO., INC (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20110082109-A1 | NOVEL ACYL GUANIDINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2011-04-07 | — | — | US | disclosed |
| US-20110082109-A1 | NOVEL ACYL GUANIDINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2011-04-07 | — | — | US | disclosed |
| US-20110082109-A1 | NOVEL ACYL GUANIDINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082109-A1 | NOVEL ACYL GUANIDINE DERIVATIVES | SLC9A3, NHERF1, SLC9A2 | F10 4727/4885PRSS1 3628/4885ERN1 1397/4885 |
| US-20120088737-A2 | NOVEL ACYL GUANIDINE DERIVATIVES | SLC9A3, NHERF1, SLC9A2 | F10 4727/4885PRSS1 3628/4885ERN1 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.